AYTU Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of 21.65% compared to Aytu BioPharma's net margin of --. Aytu BioPharma's return on equity of 5.32% beat CEL-SCI's return on equity of --.

Aytu BioPharma has a consensus price target of $9.67, signalling upside risk potential of 327.73%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 9424.76%. Given that CEL-SCI has higher upside potential than Aytu BioPharma, analysts believe CEL-SCI is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of 0.131, which suggesting that the stock is 86.935% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $18.5M, which are larger than CEL-SCI quarterly revenues of --. Aytu BioPharma's net income of $4M is higher than CEL-SCI's net income of -$6.6M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.22x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of 21.65% compared to Aytu BioPharma's net margin of -711.67%. Aytu BioPharma's return on equity of 5.32% beat IGC Pharma's return on equity of -116.24%.

Aytu BioPharma has a consensus price target of $9.67, signalling upside risk potential of 327.73%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1162.22%. Given that IGC Pharma has higher upside potential than Aytu BioPharma, analysts believe IGC Pharma is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of 0.131, which suggesting that the stock is 86.935% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.452, suggesting its more volatile than the S&P 500 by 45.212%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $18.5M, which are larger than IGC Pharma quarterly revenues of $257K. Aytu BioPharma's net income of $4M is higher than IGC Pharma's net income of -$1.8M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.22x versus 18.48x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 21.65% compared to Aytu BioPharma's net margin of -49.65%. Aytu BioPharma's return on equity of 5.32% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Aytu BioPharma has a consensus price target of $9.67, signalling upside risk potential of 327.73%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that Aytu BioPharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe Aytu BioPharma is more attractive than NovaBay Pharmaceuticals.

Aytu BioPharma has a beta of 0.131, which suggesting that the stock is 86.935% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $18.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Aytu BioPharma's net income of $4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.22x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of 21.65% compared to Aytu BioPharma's net margin of -35.79%. Aytu BioPharma's return on equity of 5.32% beat Protalix BioTherapeutics's return on equity of 10.9%.

Aytu BioPharma has a consensus price target of $9.67, signalling upside risk potential of 327.73%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 833.33%. Given that Protalix BioTherapeutics has higher upside potential than Aytu BioPharma, analysts believe Protalix BioTherapeutics is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of 0.131, which suggesting that the stock is 86.935% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $18.5M, which are larger than Protalix BioTherapeutics quarterly revenues of $10.1M. Aytu BioPharma's net income of $4M is higher than Protalix BioTherapeutics's net income of -$3.6M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 37.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.22x versus 2.10x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.